The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday.
Hence then, the article about obesity drugmaker bioage targets 158 million in ipo was published today ( ) and is available on Fortune ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Obesity drugmaker BioAge targets $158 million in IPO )
Last updated :
Also on site :
- Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
- When are London Tube strikes taking place this week and which lines are affected?
- Six Flags Is Building Another Record-Breaking Coaster—This Time With a Wild Family Twist